Effects of a Physical Exercise Program Among Diabetic Women Users of the National Health System

August 25, 2017 updated by: MARLOS RODRIGUES DOMINGUES, Federal University of Pelotas

Effects of a Physical Exercise Program Among Diabetic Women Users of the National Health System: a Randomized Clinical Trial

The study aims at evaluating the effects of an intervention among diabetic women (40 years or older) who belong to the Basic Health Units System (Brazilian public health system). The novelty of this project is that the intervention is low cost and demands very little from the health system in terms of structure, facilities and personnel.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The objective of this project is to evaluate the effect of a physical exercise program on the biochemical profile of type 2 diabetic women users of Basic Health Units (BHU) in the urban area of the city of Pelotas (Brazil). This is a randomized clinical trial, where two BHU's of the 14 eligible for the study will be drawn for inclusion in the study. Only those units with more than 100 registered diabetic patients are eligible, they also are not linked to educational institutions and do not present Physical activity projects. Four Basic Health Units (BHU) of the municipality of Pelotas (Brazil) were randomized, two for the intervention group and two for the control group. The intervention group will perform circuit-like physical exercises three times a week and the control will receive counseling to practice physical activity and meetings every 15 days with the womens to carry out walks. The program lasted 12 weeks, with three weekly sessions and presented four distinct sequences containing 10 exercises each, which were performed and circuit form and modified every three weeks. In the first week of the intervention, the women performed a passage in the circuit and with each new week a passage was increased, until the number of three passes was reached (number of passages kept fixed until the end of the intervention). Each exercise initially had a duration of 30 seconds, with a duration of 10 seconds added every three weeks up to a maximum of 60 seconds; The interval of 30 seconds between exercises was kept fixed throughout the intervention. The intensity was controlled by the subjective perception of effort. Mainly blood chemistry will be measured and evaluated.Possible confounding factors to be controlled: age, skin color, schooling, family income, weight, Body Mass Index (BMI), alcohol consumption, smoking, waist circumference, time to diagnose the disease, use of Medicines for diabetes and eating habits. The information will be collected at the baseline, at the eighth week and at the end of the study. Descriptive analyzes of the data will be performed initially, the associations will be tested by correlation, t-test and ANOVA for repeated measures. For comparisons of categorical variables, Chi-square tests will be used for heterogeneity or linear trend. The multivariate analysis will be run through logistic regression. The analyzes will be performed by intention to treat and by adherence, and the level of significance accepted for the study will be 5%. This study will seek to fill gaps in the knowledge about intervention studies in BHU's in order to identify whether physical exercise interventions with proper planning and orientation can promote improvements in the severity of the disease in diabetic women.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
120

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • Rio Grande do Sul
      • Pelotas, Rio Grande do Sul, Brazil, 96055-630
        • Physical Education School of the Federal University of Pelotas

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

40 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • females;
  • type 2 diabetic;
  • diagnosed for more than one year;
  • BMI ≥25 kg / m²;
  • age between 40 and 60 years.

Exclusion Criteria:

  • BMI ≥ 40 kg / m²;
  • history of stroke;
  • neuropathy or severe retinopathy;
  • any serious medical condition that prevents the participant to exercise safely;
  • history of severe physical disability
  • history of acute myocardial infarction in the last six months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Physical exercise intervention
Exercise group. Physical exercise intervention with sessions carried out as circuit-training, three times a week for 12 weeks to improve physical fitness and metabolic control. The sessions will last between 10 and 45 minutes.
Behavioral: Exercise group
An exercise-based program following a 12-week periodization using mostly circuit-like activities.
Active Comparator: Control
Control group consisting of women who underwent the same measurements for future comparisons and were assigned to receive information about health and counseling to practice of physical activity.
Behavioral: Control group
Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in HbA1c
Time Frame: Measured at baseline, and the end of intervention, 12th week
- Glycated hemoglobin - %
Measured at baseline, and the end of intervention, 12th week

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Glucose
Time Frame: Measured at baseline, and the end of intervention, 12th week
Fasting glucose - mg/dl
Measured at baseline, and the end of intervention, 12th week
Change in Insulin
Time Frame: Measured at baseline, and the end of intervention, 12th week
Fasting insulin - μI/ml
Measured at baseline, and the end of intervention, 12th week
Change in BP
Time Frame: Measured at baseline, and the end of intervention, 12th week
- Blood pressure - mm/hg measured with an automated equipment;
Measured at baseline, and the end of intervention, 12th week
Change in Insulin resistance
Time Frame: Measured at baseline, and the end of intervention, 12th week
Insulin resistance - Insulin (μI/L) X Fasting Glycemia (mg/dl)/405
Measured at baseline, and the end of intervention, 12th week
Change in Triglycerides
Time Frame: Measured at baseline, and the end of intervention, 12th week
Triglycerides - mg/dl
Measured at baseline, and the end of intervention, 12th week
Change in Cholesterol
Time Frame: Measured at baseline, and the end of intervention, 12th week
Total cholesterol and subfractions - mg/dl
Measured at baseline, and the end of intervention, 12th week
Change in CRP
Time Frame: Measured at baseline, and the end of intervention, 12th week
C-reactive protein - mg/l
Measured at baseline, and the end of intervention, 12th week
Change in CRF
Time Frame: Measured at baseline, and the end of intervention, 12th week
- Cardiorespiratory fitness - calculated based on the distance covered during the 6-minute walking test;
Measured at baseline, and the end of intervention, 12th week
Change in LLS
Time Frame: Measured at baseline, and the end of intervention, 12th week
- Lower limb strength - number of repetitions performed during the 30-Second Chair Stand Test;
Measured at baseline, and the end of intervention, 12th week
Change in QoL
Time Frame: Measured at baseline, and the end of intervention, 12th week
- Quality of life (SF-36) - sum of the scores of the scale.
Measured at baseline, and the end of intervention, 12th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Federal University of Pelotas

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: MARLOS R DOMINGUES, PhD, Postgraduate Program in Physical Education, Federal University of Pelotas

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 1, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2017

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 27, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 15, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 19, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 28, 2017

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 25, 2017

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2017

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • diabetes7005

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus

Clinical Trials on Exercise group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings